サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：前立腺がん診断の世界市場-2023年～2030年
市場調査レポート
商品コード
1345429

前立腺がん診断の世界市場-2023年～2030年

Global Prostate Cancer Diagnostics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
前立腺がん診断の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界の前立腺がん診断市場は、2022年に51億米ドルに達し、2023-2030年の予測期間中にCAGR 11.1％で成長し、2030年には116億米ドルに達すると予測されています。

前立腺がんは、血液中の前立腺特異抗原（PSA）値や直腸指診（DRE）の検査によって早期に発見されることが多いです。米国での研究によると、PSA検査とDREによる年1回の検診では、検診を受けない男性よりも多くの前立腺がんが発見されたが、この検診によって前立腺がんによる死亡率が低下することはありません。

前立腺がんは早期診断が重要です。病期分類が始まると、利用可能なあらゆる手技による治療が課題となります。前立腺がんは、前立腺から組織を採取してがん細胞がないか調べる前立腺生検でも診断されます。泌尿器科医の中には、生検の対象をより明確にするためにMRIや超音波の技術を用いる人もいます。PSA血液検査は、主に症状のない男性の前立腺がんのスクリーニングに使用されます。また、前立腺がんが疑われる男性に行われる最初の検査のひとつでもあります。

さらに、磁気共鳴画像法（MRI）におけるAIの統合、診断向上のための新技術の増加、男性の早期診断に対する意識の高まりが、今後数年間の市場を牽引する要因です。

ダイナミクス

パイプライン製品の増加

近年、男性の前立腺がん罹患率の上昇に伴い、前立腺がん診断の需要が増加していることから、複数のパイプライン製品が増加傾向にあります。例えば、2023年には、ランテウス社が、PSMAに結合するTc-99m標識分子であり、限局性前立腺がんだけでなく、軟部組織や骨転移を診断・検出するためのSPECT/CTイメージング剤として使用される1,404件の開発に取り組んでいます。ROTOP社は、欧州における1,404件の独占的開発・製造・販売権を有しています。

例えば、セント・ビンセント病院はクラリティ・ファーマシューティカルズ社と共同で、PSMA陰性の前立腺がんを対象に銅64 SARボンベシンを評価する第2相臨床試験を実施しました。64Cu-SAR-BBN-PETの診断ポテンシャルを探索するため、ボンベシンの放射性標識アンタゴニストアナログを使用します。終了予定は2024年6月です。

人工知能の統合による診断の改善

AIによる前立腺がん診断の調査も急速に進展しており、現在の標準的な診断経路のあらゆる側面を促進する可能性があります。さらに、AIモデルは、がん検出モデルを開発するための前立腺のセグメンテーション、MRI-超音波レジストレーション、MRI-超音波融合生検、MRI-病理組織学レジストレーションなど、労力と経験を要するがん検出の支援作業を軽減することで、がん診断を支援することができます。

例えば、2023年3月、Qritiveは高度な人工知能（AI）を搭載した前立腺がん診断ツールであるQAi Prostateを発表しました。高度な機械学習（ML）アルゴリズムを活用することで、QAi Prostateは前立腺腺がん領域を正確に特定し、生検組織サンプル中の悪性腫瘍領域と良性腫瘍領域を分類することができます。

生検手技に関連する合併症

TRUS生検には、疼痛、急性尿閉、血尿、血精液症、直腸出血、勃起不全、感染症、敗血症などのリスクが伴う。感染症や敗血症の発生率が国際的に上昇していることが懸念されます。歴史的には、TRUS生検を受けた患者の約1％が感染症を合併していましたが、近年この数字は2～4％に上昇しています。免疫不全、2型糖尿病、最近のホスピタリティ入院、COPD（慢性閉塞性肺疾患）など、敗血症の重大な危険因子を持つ男性は、TRUS生検以外の手技も考慮した方が良いでしょう。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • パイプライン製品の増加
      • 人工知能の統合による診断の向上
    • 抑制要因
      • 生検手技に関連する合併症
    • 機会
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析
  • ロシア・ウクライナ戦争の影響分析
  • DMIの見解

第6章 COVID-19分析

第7章 検査の種類別

  • 直腸指診
  • PSA血液検査
  • 生検
    • 前立腺生検
    • 経直腸生検
    • 経会陰生検
    • リンパ節生検
  • 遺伝子検査
  • 画像検査
      • 経直腸超音波検査（TRUS）
      • 磁気共鳴画像法（MRI）
      • 核医学イメージング
  • その他

第8章 がんの種類別

  • 前立腺肥大症
  • 前立腺腺がん
  • 小細胞がん
  • 管状前立腺がん
  • その他

第9章 ステージ別

  • ステージI
  • ステージII
  • ステージIII
  • ステージIV

第10章 エンドユーザー別

  • がんセンター
  • 専門クリニック
  • その他

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Myriad Genetics, Inc.
    • 企業概要
    • 製品タイプ別ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Quanterix Corporation
  • MDx Health
  • Siemens Healthineers
  • F. Hoffman-La Roche AG
  • OPKO Health, Inc
  • Thermo Fisher Scientific Inc.
  • Cellanyx Diagnostics Inc.
  • MiR Scientific LLC
  • Proteomedix

第14章 付録

目次
Product Code: CD2247

Overview

Global Prostate Cancer Diagnostics Market reached US$ 5.1 billion in 2022 and is expected to reach US$ 11.6 billion by 2030 growing with a CAGR of 11.1% during the forecast period 2023-2030.

Prostate cancer can often be found early by testing prostate-specific antigen (PSA) levels in a man's blood or digital rectal exam (DRE). According to a study in the United States, the annual screening with PSA and DRE did detect more prostate cancers than in men not screened, but this screening did not lower the prostate cancer death rate.

Early diagnosis of prostate cancer effectively is crucial. Once the staging begins, treating with any available procedure becomes challenging. It is also diagnosed with a prostate biopsy, which removes tissue from the prostate to examine it for cancer cells. Some urologists use MRI and ultrasound technology to achieve a more apparent biopsy target. The PSA blood test is used mainly to screen for prostate cancer in men without symptoms. It's also one of the first tests done in men suspecting prostate cancer.

Furthermore, the integration of AI in magnetic resonance imaging (MRI), increasing new technologies for improving diagnosis, and rising awareness about early diagnosis among males are the factors that will drive the market in the forthcoming years.

Dynamics

Rising Pipeline products

Several Pipeline products are on the rise as the demand for prostate cancer diagnosis increased in recent years due to the rising incidence of prostate cancer among males. For instance, in 2023, Lantheus is working on the development of 1404, which is a Tc-99m-labeled molecule that binds to PSMA and is used as a SPECT/CT imaging agent to diagnose and detect localized prostate cancer as well as soft tissue and bone metastases. ROTOP has exclusive rights to develop, manufacture, and commercialize 1404 in Europe.

For instance, St Vincent's Hospital collaborated with Clarity Pharmaceuticals Ltd to conduct phase 2 clinical trials to evaluate Copper-64 SAR Bombesin in PSMA Negative Prostate Cancer. Radiolabeled antagonist analog of bombesin to explore the diagnostic potential of 64Cu-SAR-BBN PET In men with rising PSA and negative PSMA PET. The estimated completion date is June 2024.

Improvements in Diagnosis with the Integration of Artificial Intelligence

Research on AI-assisted prostate cancer diagnosis is also evolving rapidly and has the potential to facilitate all aspects of the current standard diagnostic pathway. Moreover, AI models can help cancer diagnosis by reducing supporting tasks in cancer detection that are labor and experience-intensive, such as prostate gland segmentation, MRI-ultrasound registration, MRI-ultrasound fusion biopsies, and MRI-histopathology registration for developing cancer detection models.

For instance, in March 2023, Qritive introduced QAi Prostate, an advanced artificial intelligence (AI)-powered prostate cancer diagnosis tool. By leveraging advanced machine learning (ML) algorithms, QAi Prostate can accurately identify prostatic adenocarcinoma regions and classify malignant and benign tumor areas in biopsy tissue samples.

Complications related to Biopsy procedures

TRUS biopsy is associated with some risks, including pain, acute urinary retention, haematuria, haematospermia, rectal bleeding, erectile dysfunction, infection, and sepsis. The rising rates of disease and sepsis internationally are of concern. Historically, infection complicated approximately 1% of patients who underwent TRUS biopsy, but this figure has risen to 2-4% in recent years. Men with significant risk factors for sepsis, such as immunocompromise, type 2 diabetes mellitus, recent hospitalization, and COPD (Chronic obstructive pulmonary disease), could be considered for procedures other than TRUS biopsy.

Segment Analysis

The global prostate cancer diagnostics is segmented based on test type, cancer type, stage, end-user, and region.

The Segment Accounted for Approximately 45.3% of the Market Share

Prostate-specific Antigen (PSA) is a protein produced by prostate cells, and the PSA test is performed to diagnose prostate cancer (PCa) in men and for follow-up post-treatment to check if the cancer relapses. PSA testing is essential for detecting prostate cancer, which measures PSA levels in a man's blood.

Medicare and several private insurers provide coverage for an annual PSA test for all Medicare-eligible men aged 50 and older. PSA testing is gaining popularity among clinicians and hospitals owing to the increasing number of people affected by prostate cancer. For instance, on February 2023, LynxDx, Inc., a developer of innovative diagnostic solutions, is introducing MyProstateScore 2.0 (MPS2), a non-invasive, data-driven, urine prostate cancer screening test that provides highly accurate, stratified risk assessment insights to guide clinical decisions for patients with elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings. Due to increased innovations and advancements in PSA testing is expected to hold the largest market share in the forthcoming period.

Geographical Analysis

North America accounted for Approximately 39.2% of the Market Share in 2022

North America dominates the global prostate cancer diagnostics market, with the United States accounting as the primary contributor. Prostate cancer is one of the most common cancers in American men, which is made apparent by the statistics surrounding it. It affects 1 out of eight men in the U.S. after skin cancer; it is the most common cancer in U.S. men.

American Cancer Society estimated that in 2022, around 268,490 novel cases of prostate cancer were detected. Some of prostate cancers are aggressive, but most of them grow slowly. The number of deaths increases yearly, making prostate cancer the second leading cause of cancer death in men in the United States. Hence, it is considered to have an early diagnosis of the condition.

COVID-19 Impact Analysis

The effects of the pandemic on clinical trials were felt throughout administrative and clinical practices. Clinical trial initiation and recruitment were typically halted at the beginning of the pandemic as infection control measures were implemented. In a March 2021 report, a 60% decrease in new oncology clinical trials during the pandemic was noted, fueling concerns regarding slowing the development of new cancer therapies.

The focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. A major UK-based cancer research charity, Cancer Research UK, halted recruitment in 95% of their clinical trials, both to protect cancer patients and to cope with the redeployment of clinical research staff to support frontline COVID-19-facing healthcare services.

By Test Type

  • Digital Rectal Exam
  • PSA Blood Test
  • Biopsy
  • Prostate Biopsy
  • Transrectal Biopsy
  • Transperineal Biopsy
  • Lymph node Biopsy
  • Genetic Testing
  • Imaging Tests
  • Transrectal Ultrasound (TRUS)
  • Magnetic Resonance Imaging (MRI)
  • Nuclear Imaging
  • Others

By Cancer Type

  • Benign Prostate Hyperplasia
  • Prostatic Adenocarcinoma
  • Small Cell Carcinoma
  • Ductal prostate cancer
  • Others

By Stage

  • I
  • II
  • III
  • IV

By End Users

  • Cancer Centers
  • Specialty Clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • In July 2023, BPGb partnered with Grupo Terralpe to Offer AI-Discovered Prostate Cancer Diagnostic Test in Mexico. Through their strategic partnership, Grupo Terralpe will bring the pstateDx test, BPGbio's novel prostate cancer test to Mexico in an effort to improve clinical decision support for patients with elevated PSA levels who may have prostate cancer.
  • On February 2023, LynxDx, Inc., a developer of innovative diagnostic solutions is introducing MyProstateScore 2.0 (MPS2), a non-invasive, data-driven, urine prostate cancer screening test that provides highly accurate, stratified risk assessment insights to guide clinical decisions for patients with elevated prostate-specific antigen (PSA) or abnormal digital rectal exam (DRE) findings.
  • On March 2023, Novartis Pluvicto was approved by FDA as the first targeted radioligand therapy for the treatment of progressive, PSMA positive metastatic castration-resistant prostate cancer

Competitive Landscape

The major global players in the prostate cancer diagnostics market include: Myriad Genetics, Inc., Quanterix Corporation, MDx Health, Siemens Healthineers, F. Hoffman-La Roche AG, OPKO Health, Inc., Thermo Fisher Scientific Inc., Cellanyx Diagnostics Inc., MiR Scientific, and Proteomedix among others.

Why Purchase the Report?

  • To visualize the global prostate cancer diagnostics segmentation based on test type, cancer type, stage, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of prostate cancer diagnostics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global prostate cancer diagnostics market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Test Type
  • 3.2. Snippet by Cancer Type
  • 3.3. Snippet by Stage
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising Pipeline products
      • 4.1.1.2. Improvements in Diagnosis with the Integration of Artificial Intelligence
    • 4.1.2. Restraints
      • 4.1.2.1. Complications related to Biopsy procedures
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Russia-Ukraine War Impact Analysis
  • 5.6. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 7.1.2. Market Attractiveness Index, By Test Type
  • 7.2. Digital Rectal Exam
  • 7.3. PSA Blood Test
  • 7.4. Biopsy
      • 7.4.1.1. Prostate Biopsy
      • 7.4.1.2. Transrectal Biopsy
      • 7.4.1.3. Transperineal Biopsy
      • 7.4.1.4. Lymph node Biopsy
  • 7.5. Genetic Testing
  • 7.6. Imaging Tests
      • 7.6.1.1. Transrectal Ultrasound (TRUS)
      • 7.6.1.2. Magnetic Resonance Imaging (MRI)
      • 7.6.1.3. Nuclear Imaging
  • 7.7. Others

8. By Cancer Type

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 8.1.2. Market Attractiveness Index, By Cancer Type
  • 8.2. Benign Prostate Hyperplasia
  • 8.3. Prostatic Adenocarcinoma
  • 8.4. Small Cell Carcinoma
  • 8.5. Ductal prostate cancer
  • 8.6. Others

9. By Stage

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 9.1.2. Market Attractiveness Index, By Stage
  • 9.2. I
  • 9.3. II
  • 9.4. III
  • 9.5. IV

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Cancer Centers
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Specialty Clinics
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. UK
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.6.1. China
      • 11.5.6.2. India
      • 11.5.6.3. Japan
      • 11.5.6.4. Australia
      • 11.5.6.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type Market Size Analysis and Y-o-Y Growth Analysis (%), By Stage
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Myriad Genetics, Inc.
    • 13.1.1. Company Overview
    • 13.1.2. Product Type Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Quanterix Corporation
  • 13.3. MDx Health
  • 13.4. Siemens Healthineers
  • 13.5. F. Hoffman-La Roche AG
  • 13.6. OPKO Health, Inc
  • 13.7. Thermo Fisher Scientific Inc.
  • 13.8. Cellanyx Diagnostics Inc.
  • 13.9. MiR Scientific LLC
  • 13.10. Proteomedix

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us